Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Dark Forest Capital Management LP

Dark Forest Capital Management LP increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 7.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,053 shares of the medical equipment provider’s stock after purchasing an additional 223 shares during the period. Dark Forest Capital Management LP’s holdings in Hologic were worth $220,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of HOLX. Hsbc Holdings PLC raised its position in shares of Hologic by 12.5% during the 4th quarter. Hsbc Holdings PLC now owns 2,770,281 shares of the medical equipment provider’s stock valued at $199,723,000 after buying an additional 307,109 shares during the period. J. Safra Sarasin Holding AG increased its stake in Hologic by 4.3% during the fourth quarter. J. Safra Sarasin Holding AG now owns 7,150 shares of the medical equipment provider’s stock worth $515,000 after acquiring an additional 293 shares during the last quarter. TD Waterhouse Canada Inc. raised its position in Hologic by 62.8% in the fourth quarter. TD Waterhouse Canada Inc. now owns 15,315 shares of the medical equipment provider’s stock valued at $1,104,000 after purchasing an additional 5,908 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Hologic by 214.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 16,671 shares of the medical equipment provider’s stock valued at $1,202,000 after purchasing an additional 11,377 shares during the last quarter. Finally, Thematics Asset Management grew its holdings in shares of Hologic by 0.3% during the 4th quarter. Thematics Asset Management now owns 522,061 shares of the medical equipment provider’s stock worth $37,635,000 after purchasing an additional 1,368 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Up 0.5 %

Hologic stock opened at $58.36 on Wednesday. The company has a market capitalization of $13.10 billion, a P/E ratio of 18.41, a PEG ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a fifty-two week low of $55.89 and a fifty-two week high of $84.67. The stock has a 50-day simple moving average of $60.78 and a 200-day simple moving average of $69.69.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Royal Bank of Canada decreased their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Raymond James reissued an “outperform” rating and issued a $90.00 target price (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. William Blair restated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Finally, Leerink Partnrs downgraded Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.